Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.

Features and benefits

Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating depression.
Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
Understand how marketed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists.
Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.

Highlights

Datamonitor's physician survey reveals that psychiatrists perceive Forest's and Lundbeck's selective serotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superior efficacy and tolerability profile to other antidepressant brands.
TC-5214 (Targacept/AstraZeneca) and several pipeline antidepressants are poised to usurp Lexapro, following its loss of market exclusivity, and become the most attractive depression brands.
Forest's Viibryd (vilazodone) has the hallmarks of a new blockbuster - a novel mode of action, favorable tolerability, and the marketing prowess of Forest. Viibryd will be well received due to its good tolerability, although commercial success comparable to Lexapro will be unattainable as more innovative competitor drugs near the US market.

Your key questions answered

What is the gold-standard drug for depression?
How are marketed brands positioned in the depression treatment algorithm?
Which are the most likely drugs to emerge from the pipeline and how will they impact the way depression is treated?
What are the comparative strengths and weaknesses of the key depression brands and pipeline candidates?

CPI-300 (bupropion; IntelGenx)
AZD6765 (AstraZeneca)
BCI-224 (sabcomeline; BrainCells)
BCI-540 (coluracetam; BrainCells/Mitsubishi Tanabe)
BCI-952 (melatonin and buspirone; Brain Cells)
BMS-820836 (Bristol-Myers Squibb/AMRI)
Cariprazine (RGH-118; Forest/Gedeon Richter/Mitsubishi Tanabe)
Cimicoxib (UR-8880; Affectis Pharmaceuticals/Palau Pharma)
CP-601,927 (Pfizer)
EB-1010 (Euthymics Bioscience)
GLYX-13 (Naurex)
JNJ-26489112 (Johnson & Johnson)
Lu AA24530 (Lundbeck/Takeda)
OPC-34712 (Otsuka)
Orvepitant (GSK823296; GlaxoSmithKline)
PNB-01 (pipamperone and citalopram; PharmaNeuroBoost)
RG7090 (Roche)
SA4503 (cutamesine; M's Science)
Serdaxin (clavulanic acid; Rexah

简介
目录
相关商品

使用指南产品及服务须知网站导览

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

忧郁症:针对二线患者的新一代产品竞争

Product Profiles: Depression - Next generation vies for second-line patients

简介

概要

摘要整理

市场定义和概要

上市产品简介

产品线简介

参考信息

附录

目录

Description

Introduction

Features and benefits

Highlights

Your key questions answered

TOC

Executive Summary

OVERVIEW

MARKET DEFINITION AND OVERVIEW

MARKETED PRODUCT PROFILES

PIPELINE PRODUCT PROFILES

忧郁症:针对二线患者的新一代产品竞争

Product Profiles: Depression - Next generation vies for second-line patients

简介

概要

摘要整理

市场定义和概要

上市产品简介

产品线简介

参考信息

附录

目录

Description

Introduction

Features and benefits

Highlights

Your key questions answered

TOC

Executive Summary

OVERVIEW

MARKET DEFINITION AND OVERVIEW

MARKETED PRODUCT PROFILES

PIPELINE PRODUCT PROFILES

相关商品

精神病相关市场调查报告书

Datamonitor发行的制药相关市场调查报告书

Email Alert(Email 通知) - 最新市场调查报告书